Latest:
Dr. Karmali on Optimizing Maintenance Therapy in Older Patients With MCL
Reem Karmali, MD, MS, discusses next steps for optimizing maintenance therapy in older patients with mantle cell lymphoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Rena D. Callahan, MD
Latest:
Sharing the Latest in Breast Cancer Care With Drs Rena Callahan and Jame Abraham
Jame Abraham, MD, of Cleveland Clinic, and Rena D. Callahan, MD, of UCLA, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.
Renato G. Martins, MD
Latest:
Dr. Martins on Managing Toxicities Associated With Lenvatinib in DTC
Renato G. Martins, MD, medical director of Outpatient General Oncology/Hematology at Seattle Cancer Care Alliance, medical director of Thoracic/Head and Neck Oncology, and professor at the University of Washington School of Medicine, discusses side effects that are associated with lenvatinib (Lenvima).
Renato G Martins, MD, MPH
Latest:
Dr. Martins on Patient Selection for Nivolumab in NSCLC
Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).
Renuka Iyer, MD
Latest:
Dr. Iyer on Treatment of Patients With Lung NETs
Renuka Iyer, MD, associate professor of Oncology, co-director, Liver and Pancreas Tumor Center, section chief for Gastrointestinal Oncology, Roswell Park Cancer Institute, assistant professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, discusses treatment of patients with lung neuroendocrine tumors.
Reuben S. Harris, PhD
Latest:
Reuben Harris on How Tamoxifen Resistance May be Driven by APOBEC3B
Reuben S. Harris, PhD, investigator Howard Hughes Medical Institute and professor in the Department of Biochemistry, Molecular Biology, and Biophysics at the University of Minnesota College of Biological Sciences, explains the role APOBEC3B may play in tamoxifen resistance in ER-positive breast cancer.